Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Mark Schmidhofer"'
Autor:
Erin K. McCreary, Kevin E. Kip, J. Ryan Bariola, Mark Schmidhofer, Tami Minnier, Katelyn Mayak, Debbie Albin, Jessica Daley, Kelsey Linstrum, Erik Hernandez, Rachel Sackrowitz, Kailey Hughes, Christopher Horvat, Graham M. Snyder, Bryan J. McVerry, Donald M. Yealy, David T. Huang, Derek C. Angus, Oscar C. Marroquin
Publikováno v:
Learning Health Systems, Vol 6, Iss 3, Pp n/a-n/a (2022)
Abstract Introduction Rapid, continuous implementation of credible scientific findings and regulatory approvals is often slow in large, diverse health systems. The coronavirus disease 2019 (COVID‐19) pandemic created a new threat to this common “
Externí odkaz:
https://doaj.org/article/ebc78835416041d18a1729b7edb449b7
Autor:
David T. Huang, Erin K. McCreary, J. Ryan Bariola, Richard J. Wadas, Kevin E. Kip, Oscar C. Marroquin, Stephen Koscumb, Kevin Collins, Judith A. Shovel, Mark Schmidhofer, Mary Kay Wisniewski, Colleen Sullivan, Donald M. Yealy, Meredith Axe, David A. Nace, Ghady Haidar, Tina Khadem, Kelsey Linstrum, Graham M. Snyder, Christopher W. Seymour, Stephanie K. Montgomery, Bryan J. McVerry, Lindsay Berry, Scott Berry, Russell Meyers, Alexandra Weissman, Octavia M. Peck-Palmer, Alan Wells, Robert Bart, Debbie L. Albin, Tami Minnier, Derek C. Angus
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Abstract Objectives The primary objective is to evaluate the comparative effectiveness of COVID-19 specific monoclonal antibodies (mABs) with US Food and Drug Administration (FDA) Emergency Use Authorization (EUA), alongside UPMC Health System effort
Externí odkaz:
https://doaj.org/article/11a244af7e12486d9480802ecb95cd0a
Autor:
Thomas J. Woltemate, Richard J. Wadas, Erin K. McCreary, Ryan Bariola, Tami Minnier, Oscar C. Marroquin, Mark Schmidhofer, Debbie Albin, Derek C. Angus, Donald M. Yealy
Publikováno v:
Journal of the American College of Emergency Physicians Open, Vol 2, Iss 5, Pp n/a-n/a (2021)
Abstract Monoclonal antibody (mAb) therapy can improve coronavirus disease 2019 outcomes when infused early in select patients. We sought to rapidly create and implement a program for emergency department (ED) mAb infusion to aid care. Using multiple
Externí odkaz:
https://doaj.org/article/43da1956cf0c49238dd8c9ae9611ab2b
Autor:
Kevin E. Kip, Erin K. McCreary, Kevin Collins, Tami E. Minnier, Graham M. Snyder, William Garrard, Jeffrey C. McKibben, Donald M. Yealy, Christopher W. Seymour, David T. Huang, J. Ryan Bariola, Mark Schmidhofer, Richard J. Wadas, Derek C. Angus, Paula L. Kip, Oscar C. Marroquin
Publikováno v:
Annals of Internal Medicine. 176:496-504
Autor:
Erin K, McCreary, Kevin E, Kip, Kevin, Collins, Tami E, Minnier, Graham M, Snyder, Ashley, Steiner, Russell, Meyers, Tina, Borneman, Michelle, Adam, Lauren, Thurau, Donald M, Yealy, David T, Huang, J Ryan, Bariola, Mark, Schmidhofer, Richard J, Wadas, Derek C, Angus, Paula L, Kip, Oscar C, Marroquin
Publikováno v:
Open Forum Infectious Diseases. 9
Background Monoclonal antibody (mAb) treatment is associated with decreased risk of hospitalization and death in high-risk outpatients with mild to moderate coronavirus disease 2019 (COVID-19) caused by early severe acute respiratory syndrome coronav
Autor:
Jeffrey L. Carson, Maria Mori Brooks, Bernard R. Chaitman, John H. Alexander, Shaun G. Goodman, Marnie Bertolet, J. Dawn Abbott, Howard A. Cooper, Sunil V. Rao, Darrell J. Triulzi, Dean A. Fergusson, William J. Kostis, Helaine Noveck, Tabassome Simon, Philippe Gabriel Steg, Andrew P. DeFilippis, Andrew M. Goldsweig, Renato D. Lopes, Harvey White, Caroline Alsweiler, Erin Morton, Paul C. Hébert, Shahab Ghafghazi, Frances Wood, Mark Menegus, Barry Uretsky, Srikanth Vallurupalli, Gregory Maniatis, Luis Gruberg, Robert Roswell, Joseph Rossi, Farhad Abtahian, Meechai Tessalee, Gregory Barsness, Herbert Aronow, Kodangudi Ramanathan, Mark Schmidhofer, Friederike Keating, Michael Carson, Michael Kontos, Mansoor Qureshi, Stacey Clegg, Warren Laskey, Tamar Polonsky, Rajesh Gupta, Mujeeb Abdul Sheikh, Lynne Uhl, Paul Mullen, Arthur Bracey, William Matthai, Christopher Stowell, David Dudzinski, Gregary Marhefka, Perry Weinstock, William Lawson, Norma Keller, Eugene Yuriditsky, Michael Thomas, Alice Jacobs, Claudia Hochberg, Omar Siddiqi, Joshua Schulman-Marcus, Mikhail Torosoff, Michael Gitter, Xuming Dai, Jay Traverse, Eric McCamant, Jason Scott, Rajesh Swaminathan, Sunil Rao, Adam Salisbury, David Landers, Ganesh Raveendran, Ramin Ebrahimi, Richard Bach, Joseph Delehanty, Raj C. Shah, Sorin Brener, Jonathan Doroshow, Adriano Caixeta, Dalton Precoma, Frederico Toledo Campo Dall'Orto, Pedro Beraldo De Andrade, Marianna Dracoulakis, Lília Nigro Maia, Luiz Eduardo Fontelles Ritt, Alexandre Quadros, Dário Celestino Sobral Filho, Fernando De Martino, Thao Huynh, Greg Schnell, Manohara Senaratne, Vikas Tandon, John Neary, David Laflamme, Jean-Pierre Dery, Kevin Bainey, Richard Haichin, Payam Dehghani, Ata Ur Rehman Quraishi, Brian J. Potter, François Martin Carrier, Michael Goldfarb, Christopher Fordyce, Ying Tung Sia, Benoit Daneault, Mina Madan, Terry McPherson, John Ducas, Kunal Minhas, Neil Brass, Akshay Bagai, Simon Robinson, Vladimír Džavík, Razi Khan, Nicolas Michaud, Gabriel Steg, Gregory Ducrocq, Etienne Puymirat, Gilles Lemesle, Emile Ferrari, Benoit Lattuca, Johanne Silvain, Gérald Vanzetto, Laura Cetran, Thibault Lhermusier, Yves Cottin, Yann Rosamel, Denis Angoulvant, Jean Guillaume Dillinger, Christophe Thuaire, Batric Popovic, Eric Durand, Claire Bouleti, François Roubille, Laurent Delorme, Ian Crozier, Jocelyne Benatar, Samraj Nandra, Ian Ternouth, Nick Fisher, David Brieger, Graham Hillis
Publikováno v:
American heart journal.
Accumulating evidence from clinical trials suggests that a lower (restrictive) hemoglobin threshold (8% g/dL) for red blood cell (RBC) transfusion, compared with a higher (liberal) threshold (≥10 g/dL) is safe. However, in anemic patients with acut
Autor:
Patrick J. Coppler, Jonathan Elmer, Ankur A. Doshi, Francis X. Guyette, Masashi Okubo, Cecelia Ratay, Adam N. Frisch, Alexis Steinberg, Alexandra Weissman, Valerie Arias, Byron C. Drumheller, Katharyn L. Flickinger, John Faro, Mark Schmidhofer, Zachary J. Rhinehart, Barinder S. Hansra, Joanna Fong-Isariyawongse, Niravkumar Barot, Maria E. Baldwin, A. Murat Kaynar, Joseph M. Darby, Lori A. Shutter, Joseph Mettenburg, Clifton W. Callaway
Publikováno v:
Resuscitation. 188:109823
Autor:
Michael Bashline, Julie DiBridge, Wyatt J. Klass, Brian Morelli, David Kaczorowski, Mark Schmidhofer, Edward T. Horn, Hernando Gomez, Raj Ramanan, Gavin W. Hickey, Ryan M. Rivosecchi
Publikováno v:
Artificial organsREFERENCES.
Impella 5.5 (Abiomed; Danvers, MA) (IMP5) is a commonly used, surgically implanted, tMCS device that requires systemic anticoagulation and purge solution to avoid pump failure. To avoid heparin-induced thrombocytopenia (HIT) from unfractionated hepar
Autor:
Douglas B. White, Erin K. McCreary, Chung-Chou H. Chang, Mark Schmidhofer, J. Ryan Bariola, Naudia N. Jonassaint, Govind Persad, Robert D. Truog, Parag Pathak, Tayfun Sonmez, M. Utku Unver
Publikováno v:
American journal of respiratory and critical care medicine. 206(4)
Autor:
Erin K. McCreary, J. Ryan Bariola, Richard J. Wadas, Judith A. Shovel, Mary Kay Wisniewski, Michelle Adam, Debbie Albin, Tami Minnier, Mark Schmidhofer, Russell Meyers, Oscar C. Marroquin, Kevin Collins, William Garrard, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Kelsey Linstrum, Anna Nakayama, Stephanie K. Montgomery, Graham M. Snyder, Donald M. Yealy, Derek C. Angus, Paula L. Kip, Christopher W. Seymour, David T. Huang, Kevin E. Kip
Publikováno v:
JAMA network open. 5(4)
Monoclonal antibody (mAb) treatment decreases hospitalization and death in high-risk outpatients with mild to moderate COVID-19; however, only intravenous administration has been evaluated in randomized clinical trials of treatment. Subcutaneous admi